Navigation Links
First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
Date:8/27/2007

tube carcinoma. Eur J Gynaecol Oncol. 2005;26(4):386-90.

(2) van der Burg ME, van der Gaast A, Vergote I, Burger CW, van Doorn HC,

de Wit R, Stoter G, Verweij J. What is the role of dose-dense therapy?

Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:233-240.

(3) CaDron I, Leunen K, Amant F, Van Grop T, Neven P, Vergote I. The

"Leuven" dose dense paclitaxel/carboplatin regimen in patients with

recurrent ovarian cancer. Gynecol Oncol 2007, in press.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third arty patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acc
'/>"/>

SOURCE Novogen Limited
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008).../- CEL-SCI Corporation,(NYS... a Material Transfer,Agreement (MTA) with the Nati...and the laboratory of Dr. Francesco M. Marincola, ...s to the tumor microenvironment,caused by CEL-SCI,...f of,the Infectious Disease and Immunogentics Sect...
(Date:10/7/2008)...d Today at ACG Annual Scientific Meeting -, ORLAN...d,Pharmaceuticals, Inc. (formerly Microbia, Inc.) ...announced the presentation of results from a Phase...acy in 420 patients with,irritable bowel syndrome ...dicates that once- daily oral dosing of linaclotid...
(Date:10/7/2008)...ghlighting CIMZIA,s long-term benefits and value i...ented at American College,of Gastroenterology (ACG... Data from two studies,presented this week by UCB ...Annual Meeting demonstrate that CIMZIA(R) (certoli...Tumor Necrosis Factor alpha) - provides,sustained ...
(Date:10/7/2008)...hort Enrolled in Stage A of Trial Assessing Regime...n and Paclitaxel -, TUSTIN, Calif., Oct. 7 /PRNew.... (Nasdaq: PPHM ), a clinical stage biopharmaceut...the treatment of cancer and,hepatitis C virus (HCV...,enrollment in the first stage of a Phase II trial...
Breaking Medicine Technology:CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4U S Research Funding Continues to Flatten as U S Health Costs Climb in August 31 Science 258 1U S Research Funding Continues to Flatten as U S Health Costs Climb in August 31 Science 258 2Cepheid to Present at Thomas Weisel Partners Healthcare Conference 282 1Cepheid to Present at Thomas Weisel Partners Healthcare Conference 282 2Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 280 1Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 280 2Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 280 3Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference 278 1Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference 278 2
(Date:10/7/2008)...published ACSM/AHA, guidelines, INDIANAPOLIS and...nes,for physical activity released today by the U....ere met with support from the American College of,...ciation (AHA). The,organizations, which jointly pu...r, attended today,s announcement and said the guid...
(Date:10/7/2008)ANAHEIM, Calif., Oct. 7 /PRNewswire-USNewswire/ -- CHADD, the nation,s,largest organization serving people affected by AD/HD, will hold its Annual,International Conference on AD/HD November 12-1
(Date:10/7/2008)...sive whole-leg color ultrasound, study finds, ...An older, simpler test to look for blood clots in ...is as effective as a newer, more expensive test, n...that 2-point ultrasonography of the leg -- sometim...as good at detecting DVT as the newer, whole-leg, ...
(Date:10/7/2008)... the University of California, San Diego (UCSD) in...arch of advanced lung cancer by treating patients ...ccines attempt to pump up the immune system to fig...tically engineered to also trick the cancer into t...s. , The first patients have begun enrolling in ...
Breaking Medicine News(10 mins):Health News:ACSM, AHA Support Federal Physical Activity Guidelines 2Health News:ACSM, AHA Support Federal Physical Activity Guidelines 3Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 3Health News:Novel Lung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center 2
... and college students are now co-authors in a rese...erisation of 30 macrophages has been made possible...ue of June 9, 2006 has a report of a research team...m Hatfull at the University of Pittsburgh. The rep...
...nal of Clinical Nutrition says that the poor healt...r the overweight/obesity epidemic that has the soc...betel nut, it was found that they passed the habit... Boucher, of the University of London, and colleag...
...r that actually quietens the body’s natural pain k...t and non-habit //forming pain killers and will he...Opioid peptides are natural pain relievers with re...y react to opium – throughout the body, says Dr. V...
...tute of Allergy and Infectious Diseases (NIAID), s...r the intended //protection against infection, yet...vaccinated. Such a survival advantage was observe...eams of researchers, one led by Norman L. Letvin, ...
Other Medicine News:Health News:Transporter offers reliable clues for safer pain medicine 2Health News:Transporter offers reliable clues for safer pain medicine 3Health News:HIV Vaccine for Monkeys Increases Survival Rates 2Health News:HIV Vaccine for Monkeys Increases Survival Rates 3
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
Medicine Products: